|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed an integrated cytogenetic study using a combination of comparative genomic hybridization (CGH), spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH) to analyze chromosomal aberrations associated with 8 human esophageal squamous cell carcinoma (EC-SCC) cell lines, and used real-time quantitative PCR (Q-PCR) to study the copy number changes of two candidate genes of chromosome 3q, PIK3CA and TP63, in 20 primary tumors of EC-SCC.
|
12963965 |
2003 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study analyzed the clinical effect of messenger RNA (mRNA) expression for PIK3CA (the gene that encodes phosphatidylinositol-3 kinase catalytic alpha-polypeptide) and TFRC (the gene that encodes the transferrin receptor), which map within chromosome 3q in ESCC.
|
16788758 |
2006 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
|
18262558 |
2008 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated the mRNA levels of four candidate genes (TERC, SCCRO, EVI-1, and SnoN) to determine whether genes other than PIK3CA are targets for amplification at 3q26 in ESCC.
|
18612694 |
2008 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemically, positive immunoreaction for PIK3CA was detectable in 33 of 66 (50.0%) ESCC cases, while it was not detectable in the remaining 33 cases.
|
19212681 |
2009 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that downregulation of HMW TMs occurs basically in SCCE and the activation of MEK/ERK and PI3K/Akt pathways as well as the epigenetic mechanism of promoter hypermethylation play important role in TM1 suppression in SCCE.
|
22965424 |
2012 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the influence of PIK3CA mutations on the prognosis of patients with esophageal squamous cell carcinoma (ESCC) remains unclear.
|
23532889 |
2013 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, patients with PIK3CA-mutated tumors showed a trend towards favorable overall survival (P = .085) but not disease-free survival (P = .238), suggesting that PIK3CA gene status may be a favorable predictive marker in ESCC patients.
|
24360885 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
EGFR:rs2227983 and 3 SNPs of PIK3CA also showed borderline significant correlation with OS of advanced ESCC patients (P = 0.058 for rs2227983; P = 0.069, 0.091 and 0.067 for rs6443624, rs7651265 and rs7621329 of PIK3CA respectively).
|
24945674 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Direct sequencing was applied to investigate mutations in exons 9 and 20 of PIK3CA in 406 Chinese ESCC patients.
|
25054828 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, the level of miR-508 correlates with poor survival and activated PI3K/Akt signalling in a large cohort of ESCC specimens.
|
25099196 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disruption of the PTEN/PI3K pathway involved in TGF-β1-induced EMT may provide possible routes for therapeutic intervention to ESCC.
|
25175594 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously revealed genetic and epigenetic alterations associated with esophageal SCCs in relation to clinical outcome, including mutations in KRAS, BRAF, and PIK3CA, p53 expression, and long interspersed nucleotide element-1 (LINE-1) methylation, a surrogate marker for global DNA methylation level.
|
25691283 |
2015 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, high activity of hedgehog signaling and the PI3K pathway in approximately 60% of 104 ESCC tumors indicates that therapies targeting these pathways might be particularly promising strategies for ESCC.
|
25839328 |
2015 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways.
|
25843419 |
2015 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway.
|
26191164 |
2015 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In two independent cohorts of ESCC samples (n = 20 and n = 53, respectively), Kindlin-2 expression positively correlated with the activation status of both the integrin signaling pathway and the PI3K-AKT signaling pathway (both P < 0.01).
|
26334393 |
2015 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified statistically significant mutual exclusivity between mutations in NOTCH1 and PIK3CA in ESCC samples.
|
26528858 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although the cancer-associated genes TP53, PIK3CA, CDKN2A and their pathways showed no significant difference between stage I and stage III tumors, we identified and validated a prevalence of mutations in NOTCH1 and in the NOTCH pathway that indicate that they are involved in the preclinical and early stages of ESCC.
|
26759717 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that copy number loss of Variation_91720 in PIK3CA predicts risk of ESCC, which might serve as a biomarker that for early diagnosis of ESCC.
|
26823766 |
2015 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated APOBEC3B expression in ESCC and investigated the relationships among the immunoreactivity of APOBEC3B, clinical and pathological features, and the molecular features of ESCC (PIK3CA mutation, p53 expression, and LINE-1 methylation level).
|
26880326 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of PIK3CA was significantly higher in ESCC than in paired normal controls and was ethnicity independent; no statistically significant difference was observed between PIK3CA expression and sex, age, depth of invasion, tumor differentiation, lymph node metastasis, or prognosis.
|
27001433 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
PIK3CA amplification may represent a promising therapeutic target for ESCC.
|
27095573 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further study revealed that MMP1 facilitated ESCC through the activation of the PI3K/AKT pathway.
|
27130665 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the PI3K/Akt signaling pathway in HPV16 positive tissues is an available therapeutic for ESCC patients.
|
27489353 |
2016 |